Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour - PubMed (original) (raw)

Review

Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour

Shanshan Han et al. Cochrane Database Syst Rev. 2010.

Update in

Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour.
Han S, Crowther CA, Moore V. Han S, et al. Cochrane Database Syst Rev. 2013 May 31;2013(5):CD000940. doi: 10.1002/14651858.CD000940.pub3. Cochrane Database Syst Rev. 2013. PMID: 23728634 Free PMC article. Review.

Abstract

Background: Magnesium maintenance therapy is one of the types of tocolytic therapy used after an episode of threatened preterm labour (usually treated with an initial dose of tocolytic therapy) in an attempt to prevent the onset of further preterm contractions.

Objectives: To assess whether magnesium maintenance therapy is effective in preventing preterm birth after the initial threatened preterm labour is arrested.

Search strategy: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (May 2010).

Selection criteria: Randomised controlled trials of magnesium therapy given to women after threatened preterm labour.

Data collection and analysis: The review authors independently assessed the studies for inclusion, assessed risk of bias and carried out data extraction. We checked data entry.

Main results: We included four trials, which recruited 422 women. Three trials had high risk of bias and none included any long-term follow up of infants. No differences in the incidence of preterm birth or perinatal mortality were seen when magnesium maintenance therapy was compared with placebo or no treatment; or alternative therapies (ritodrine or terbutaline). The risk ratio (RR) for preterm birth (less than 37 weeks) for magnesium compared with placebo or no treatment was 1.05, 95% confidence interval (CI) 0.80 to 1.40 (two trials, 99 women); and 0.99, 95% CI 0.57 to 1.72 (2 trials, 100 women) for magnesium compared with alternative therapies. The RR for perinatal mortality for magnesium compared with placebo or no treatment was 5.00, 95% CI 0.25 to 99.16 (one trial, 50 infants) and also compared with alternative treatments, was 5.00, 95% CI 0.25 to 99.16 (one trial, 50 infants). Women taking magnesium preparations were less likely to report palpitations or tachycardia than women receiving alternative therapies (RR 0.26, 95% CI 0.13 to 0.52, three trials, 237 women) but were much more likely to experience diarrhoea (RR 7.66, 95% CI 2.18 to 26.98, three trials, 237 women).

Authors' conclusions: There is not enough evidence to show any difference between magnesium maintenance therapy compared with either placebo or no treatment, or alternative therapies (ritodrine or terbutaline) in preventing preterm birth after an episode of threatened preterm labour.

PubMed Disclaimer

Update of

Magnesium for preventing preterm birth after threatened preterm labour.
Crowther CA, Moore V. Crowther CA, et al. Cochrane Database Syst Rev. 2000;(2):CD000940. doi: 10.1002/14651858.CD000940. Cochrane Database Syst Rev. 2000. PMID: 10796222 Updated. Review.

Cited by

Vaginal progesterone vs. cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis.
Conde-Agudelo A, Romero R, Nicolaides K, Chaiworapongsa T, O'Brien JM, Cetingoz E, da Fonseca E, Creasy G, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan SS. Conde-Agudelo A, et al. Am J Obstet Gynecol. 2013 Jan;208(1):42.e1-42.e18. doi: 10.1016/j.ajog.2012.10.877. Epub 2012 Nov 15. Am J Obstet Gynecol. 2013. PMID: 23157855 Free PMC article. Review.
Prevention and Therapy of Preterm Birth. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry Number 015/025, February 2019) - Part 2 with Recommendations on the Tertiary Prevention of Preterm Birth and the Management of Preterm Premature Rupture of Membranes.
Berger R, Abele H, Bahlmann F, Bedei I, Doubek K, Felderhoff-Müser U, Fluhr H, Garnier Y, Grylka-Baeschlin S, Helmer H, Herting E, Hoopmann M, Hösli I, Hoyme U, Jendreizeck A, Krentel H, Kuon R, Lütje W, Mader S, Maul H, Mendling W, Mitschdörfer B, Nicin T, Nothacker M, Olbertz D, Rath W, Roll C, Schlembach D, Schleußner E, Schütz F, Seifert-Klauss V, Steppat S, Surbek D. Berger R, et al. Geburtshilfe Frauenheilkd. 2019 Aug;79(8):813-833. doi: 10.1055/a-0903-2735. Epub 2019 Aug 12. Geburtshilfe Frauenheilkd. 2019. PMID: 31423017 Free PMC article.
Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth.
Bain E, Middleton P, Crowther CA. Bain E, et al. Cochrane Database Syst Rev. 2012 Feb 15;2012(2):CD009302. doi: 10.1002/14651858.CD009302.pub2. Cochrane Database Syst Rev. 2012. PMID: 22336863 Free PMC article. Review.
A Study on the Association between Low Maternal Serum Magnesium Level and Preterm Labour.
Okunade KS, Oluwole AA, Adegbesan-Omilabu MA. Okunade KS, et al. Adv Med. 2014;2014:704875. doi: 10.1155/2014/704875. Epub 2014 Apr 13. Adv Med. 2014. PMID: 26556421 Free PMC article.
Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour.
Han S, Crowther CA, Moore V. Han S, et al. Cochrane Database Syst Rev. 2013 May 31;2013(5):CD000940. doi: 10.1002/14651858.CD000940.pub3. Cochrane Database Syst Rev. 2013. PMID: 23728634 Free PMC article. Review.

Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour - PubMed (original) (raw)